Purpose: This study aimed to evaluate the functional and anatomical effects of switching to faricimab in patients with polypoidal choroidal vasculopathy (PCV) refractory to other anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods: This retrospective study analyzed the medical records of patients with PCV who were switched to faricimab. Prior to the initial faricimab injections, all patients underwent spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography, and indocyanine green angiography. Changes in best-corrected visual acuity were recorded, while anatomic outcomes including central macular thickness (CMT), subfoveal choroidal thickness (SFCT), pigment epithelial detachment (PED) height, and presence of retinal fluid were measured by SD-OCT. Results: A total of 19 eyes from 17 patients were included. The mean age was 71.3 ± 7.3 years. Prior to faricimab treatment, patients had received a mean of 20.2 ± 9.5 (range 8–40) injections. The mean follow-up duration from the initial faricimab injection was 38.6 ± 17.6 weeks (range 16–68). At baseline, the mean CMT, PED height, and SFCT were 443.8 ± 220.9 µm, 331.0 ± 389.3 µm, and 289.5 ± 148.9 µm, respectively. During faricimab treatment, significant anatomical improvements were observed in CMT (314.9 ± 110.5 µm), PED height (158.0 ± 152.5 µm), and SFCT (239.0 ± 110.1 µm) (all p < 0.05). A good PED response (≥50% reduction in height) was achieved in 7 eyes (41.1%), a partial response (<50% reduction) in 7 eyes (41.1%), and a poor response (no change in height) in 3 eyes (17.6%). At the final visit, 11 eyes (57.8%) achieved a dry macula, representing the absence of intraretinal or subretinal fluid. Conclusions Faricimab may represent a safe and effective treatment strategy for improving anatomical outcomes, though larger patient cohorts are required to validate these findings. This drug could emerge as a valuable alternative for patients experiencing PCV refractory to other anti-VEGF injections.

Methemoglobinemia (MetHb), which is characterized by an increased methemoglobin level, is a rare but potentially fatal disorder caused by congenital enzyme deficiencies or exposure to oxidizing agents, including dapsone. Elevation in the methemoglobin level impairs the oxygen-carrying capacity of hemoglobin, produces functional anemia, and induces tissue hypoxia. Such hypoxia results in microcirculation injury and hypoperfusion in the tissue and organs, including the kidney, and is a risk factor for acute kidney injury (AKI). This paper reports a case of AKI caused by dapsone-induced MetHb in a patient with chronic kidney disease, in which the patient ingested approximately 1,500 mg of dapsone in a suicide attempt, which was treated with aggressive management, including methylene blue, ascorbic acid, and transfusion.

No abstract available.
Nail Diseases ; Nails, Malformed ; Melanoma ; Skin Neoplasms

No abstract available.
Korea*

PURPOSE: People with a family history of mood disorder are more likely to have depression. This study compared the characteristics of non-psychotic major depression disorder according to family history of depression. METHOD: Subjects were total of 817 persons recruited for the CRESCEND-K multicenter trial. Characteristics of depression and suicide history of patients with and without a family history of depression were assessed. Family history was determined through self-report. RESULTS: Of 817 participants, 12.4% had a positive family history of depression. Those with family history of depression reported an earlier age at onset of MDD, and more psychiatric comorbidity. Severity of depression and anxiety were not different according to family history of depression. There were no difference in attempted suicide history, number of attempted suicide and age at onset of 1st attempted suicide according to such a family history. CONCLUSION: Patients with family history of depression reported earlier onset of MDD and more history of psychiatric comorbidity.
Anxiety ; Comorbidity ; Depression ; Depressive Disorder, Major ; Humans ; Mood Disorders ; Suicide ; Suicide, Attempted